{"id":"treatment-5","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":{"setId":"4cb728d0-6abe-6645-e063-6394a90acb4c","title":"IBEALEE 5% MINOXIDIL HAIR REGROWTH TREATMENT (5% MINOXIDIL) SPRAY [SHENZHEN EARTH SURFACE TRADING CO., LTD.]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Treatment 5 is a treatment that targets","oneSentence":"Treatment 5 works by","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T05:33:45.207Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05622136","phase":"PHASE2","title":"Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2023-09-10","conditions":"Liver Cancer, Hepatocellular Carcinoma","enrollment":28},{"nctId":"NCT06097663","phase":"PHASE2","title":"A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-15","conditions":"Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)","enrollment":31},{"nctId":"NCT06868914","phase":"PHASE1","title":"Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)","status":"NOT_YET_RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2026-04-01","conditions":"Healthy Volunteers","enrollment":35},{"nctId":"NCT04439201","phase":"PHASE2","title":"Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-31","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":40},{"nctId":"NCT02466971","phase":"PHASE3","title":"Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-10","conditions":"Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma","enrollment":450},{"nctId":"NCT03856229","phase":"NA","title":"Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS","status":"ENROLLING_BY_INVITATION","sponsor":"Centro de Investigación en. Enfermedades Infecciosas, Mexico","startDate":"2019-03-04","conditions":"Pneumocystis, HIV/AIDS, Steroid","enrollment":196},{"nctId":"NCT07348120","phase":"NA","title":"Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2025-05-01","conditions":"Telogen Effluvium","enrollment":60},{"nctId":"NCT06857929","phase":"NA","title":"\"Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition\"","status":"RECRUITING","sponsor":"IMDEA Food","startDate":"2026-03-01","conditions":"Metabolic Syndrome, Obesity Prevention, Obesity and Overweight","enrollment":106},{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT07495553","phase":"NA","title":"WEB-BASED FILIAL THERAPY IN PEDIATRIC CANCER","status":"COMPLETED","sponsor":"serap güleç keskin","startDate":"2023-09-25","conditions":"Pediatric Cancer, Parental Stress, Parenting Anxiety","enrollment":60},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06925737","phase":"PHASE3","title":"A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-05-13","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":1440},{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow","enrollment":312},{"nctId":"NCT05600894","phase":"PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts","enrollment":132},{"nctId":"NCT07454330","phase":"NA","title":"Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-02-27","conditions":"Cancer, Survivorship","enrollment":64},{"nctId":"NCT07156227","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-22","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma","enrollment":39},{"nctId":"NCT07480174","phase":"NA","title":"Effects of Tai Chi and Yoga on Flexibility, Anxiety, and Sleep Quality in Women","status":"RECRUITING","sponsor":"Istanbul University - Cerrahpasa","startDate":"2026-03-14","conditions":"Healthy Lifestyle","enrollment":40},{"nctId":"NCT06514261","phase":"PHASE1","title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-18","conditions":"Acute Myeloid Leukemia","enrollment":45},{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260},{"nctId":"NCT07496632","phase":"NA","title":"Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients\"","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Medical University","startDate":"2026-04","conditions":"Scalp Block","enrollment":72},{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":"Lymphoma","enrollment":129},{"nctId":"NCT05053971","phase":"PHASE1, PHASE2","title":"Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-16","conditions":"Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma","enrollment":49},{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":"Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency, Immune System Diseases","enrollment":354},{"nctId":"NCT06475651","phase":"","title":"Characterization and Contribution of Genome-wide DNA Methylation (DNA Methylation Episignatures) in Rare Diseases With Prenatal Onset","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-02-26","conditions":"Rare Fetal Genetic Diseases, Congenital Malformation","enrollment":63},{"nctId":"NCT06356610","phase":"NA","title":"Pharmacokinetic and Subjective Effects of Heated Tobacco Products","status":"COMPLETED","sponsor":"Altria Client Services LLC","startDate":"2024-02-06","conditions":"Tobacco Use","enrollment":80},{"nctId":"NCT04387656","phase":"","title":"NCI COVID-19 in Cancer Patients, NCCAPS Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-05","conditions":"COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":1877},{"nctId":"NCT04958265","phase":"PHASE3","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-11-17","conditions":"Atypical Hemolytic Uremic Syndrome","enrollment":41},{"nctId":"NCT05702853","phase":"PHASE1, PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"B-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia","enrollment":27},{"nctId":"NCT07493993","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-06-01","conditions":"ESCC","enrollment":26},{"nctId":"NCT07281638","phase":"NA","title":"Bedside Bike Early Mobilization Program for Inpatients","status":"NOT_YET_RECRUITING","sponsor":"Indiana University","startDate":"2026-07-05","conditions":"Immobility Syndrome, Deep Venous Thrombosis, Delirium","enrollment":80},{"nctId":"NCT06751589","phase":"EARLY_PHASE1","title":"A Study of a Weight Loss Intervention in People With Endometrial Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-12-19","conditions":"Endometrial Cancer","enrollment":36},{"nctId":"NCT04284787","phase":"PHASE2","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":60},{"nctId":"NCT07450833","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers","status":"COMPLETED","sponsor":"Benfovir AG","startDate":"2022-03-01","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT04052555","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-24","conditions":"Bilateral Breast Carcinoma, HER2-Negative Breast Carcinoma, Localized Breast Carcinoma","enrollment":42},{"nctId":"NCT04943224","phase":"PHASE2","title":"Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients","status":"RECRUITING","sponsor":"Anna Raciborska","startDate":"2021-04-01","conditions":"Histiocytosis","enrollment":12},{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT07497958","phase":"NA","title":"Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-04-01","conditions":"Renal Cell Carcinoma (RCC), Renal Function Abnormal","enrollment":174},{"nctId":"NCT01468896","phase":"PHASE1, PHASE2","title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-26","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma","enrollment":23},{"nctId":"NCT07264543","phase":"PHASE2, PHASE3","title":"Early Methylene Blue in the Microhemodynamics of Septic Patients","status":"RECRUITING","sponsor":"Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva","startDate":"2026-01-09","conditions":"Septic Shock, Hypoperfusion","enrollment":50},{"nctId":"NCT04310020","phase":"PHASE2","title":"Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-13","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":47},{"nctId":"NCT02159755","phase":"PHASE1","title":"Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-08-13","conditions":"Recurrent Mantle Cell Lymphoma","enrollment":28},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT06126276","phase":"PHASE2","title":"Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-05-07","conditions":"Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm","enrollment":70},{"nctId":"NCT00268385","phase":"PHASE1","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-12-16","conditions":"Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma","enrollment":83},{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT05372640","phase":"PHASE1","title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":45},{"nctId":"NCT05941520","phase":"PHASE2","title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-23","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":80},{"nctId":"NCT06890026","phase":"","title":"Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-15","conditions":"Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve","enrollment":742},{"nctId":"NCT06498648","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-18","conditions":"Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Soft Tissue Sarcoma","enrollment":74},{"nctId":"NCT06948448","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-11-18","conditions":"Colorectal Cancer","enrollment":144},{"nctId":"NCT06459180","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-24","conditions":"Cervical Cancer","enrollment":686},{"nctId":"NCT06023537","phase":"NA","title":"Using Technology to Investigate Lapses in a Weight Loss Program Among Individuals With Overweight and Obesity","status":"COMPLETED","sponsor":"Williams College","startDate":"2023-07-11","conditions":"Obesity, Weight Loss","enrollment":119},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT05490771","phase":"PHASE2","title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":35},{"nctId":"NCT05462730","phase":"PHASE2","title":"Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Thomas Engstrom","startDate":"2022-11-14","conditions":"ST Elevation Myocardial Infarction, Inflammatory Response, Myocardial Reperfusion Injury","enrollment":530},{"nctId":"NCT07496008","phase":"","title":"Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-25","conditions":"Isavuconazole, Invasion Pulmonary Mycosis","enrollment":150},{"nctId":"NCT05213234","phase":"NA","title":"Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2021-07-09","conditions":"Ulcerative Colitis","enrollment":32},{"nctId":"NCT06869447","phase":"NA","title":"New York Better Breathing Study","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-04-15","conditions":"Localized Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":100},{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT07424404","phase":"PHASE3","title":"A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2026-03-31","conditions":"Schizophrenia, Autism-Related Irritability","enrollment":400},{"nctId":"NCT04527406","phase":"NA","title":"Early Surgical Intervention of Congenital Hemivertebra in Young Children","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-01","conditions":"Congenital Hemivertebra","enrollment":""},{"nctId":"NCT00658814","phase":"PHASE2","title":"Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12-01","conditions":"Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":133},{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT06949969","phase":"NA","title":"Alesis OSA-1 Obstructive Sleep Apnea Treatment","status":"COMPLETED","sponsor":"Photonica USA, LLC","startDate":"2025-05-01","conditions":"Obstructive Sleep Apnea","enrollment":35},{"nctId":"NCT07497841","phase":"NA","title":"Development and Validation of a KAP Questionnaire for Secondary Hypertension: Evaluating a Community Short-Video Intervention in Rural Beijing","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2025-12-01","conditions":"Secondary Hypertension","enrollment":1062},{"nctId":"NCT02595931","phase":"PHASE1","title":"M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-07-22","conditions":"Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm","enrollment":66},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":"Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma","enrollment":325},{"nctId":"NCT06317649","phase":"PHASE2","title":"Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-27","conditions":"Acute Myeloid Leukemia","enrollment":147},{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":"Shift Work Schedule, Circadian Rhythm, Insulin Resistance","enrollment":24},{"nctId":"NCT04986566","phase":"NA","title":"Perioperative Telemonitoring to Optimize Cancer Care and Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-10-19","conditions":"Malignant Digestive System Neoplasm","enrollment":134},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT06669299","phase":"NA","title":"Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies","status":"RECRUITING","sponsor":"IRCCS Ospedale San Raffaele","startDate":"2025-06-12","conditions":"Ventricular Tachycardia (VT)","enrollment":51},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT06044935","phase":"NA","title":"Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2024-01-08","conditions":"Overweight, Obesity","enrollment":100},{"nctId":"NCT07293676","phase":"NA","title":"IASTM and Vibration Effects on Pain, Functionality, and Kinesiophobia in Lumbar Disc Herniation","status":"RECRUITING","sponsor":"Istanbul Medipol University Hospital","startDate":"2026-01-05","conditions":"Vibration, Lumbar Disc Herniation, Soft Tissue Mobilization","enrollment":45},{"nctId":"NCT07491302","phase":"PHASE2","title":"Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection","status":"NOT_YET_RECRUITING","sponsor":"Goed Medisch Centrum","startDate":"2026-03","conditions":"Thumb Osteoarthritis","enrollment":88},{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Malaria","enrollment":400},{"nctId":"NCT00980460","phase":"PHASE3","title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-14","conditions":"PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma","enrollment":236},{"nctId":"NCT07140380","phase":"PHASE2","title":"Phase 2b Controlled Study","status":"COMPLETED","sponsor":"IVIEW Therapeutics Inc.","startDate":"2025-08-20","conditions":"Dry Eye Disease","enrollment":30},{"nctId":"NCT02231840","phase":"","title":"NIAAA Natural History Protocol","status":"RECRUITING","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2015-01-21","conditions":"Alcohol Use Disorder","enrollment":7500},{"nctId":"NCT05859347","phase":"NA","title":"Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder","status":"RECRUITING","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-05-15","conditions":"Cannabis Use Disorder","enrollment":46},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT05432804","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-20","conditions":"MGMT-Methylated Glioblastoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma","enrollment":97},{"nctId":"NCT06998940","phase":"PHASE3","title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-04-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8","enrollment":94},{"nctId":"NCT07498088","phase":"NA","title":"THE EFFECT OF HAPTONOMY PRACTICE ON PREGNANT WOMEN WITH A HISTORY OF ABORTION.","status":"NOT_YET_RECRUITING","sponsor":"Uskudar University","startDate":"2026-03-30","conditions":"Pregnant Women","enrollment":80},{"nctId":"NCT07495670","phase":"NA","title":"Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients","status":"COMPLETED","sponsor":"Burapha University","startDate":"2024-11-04","conditions":"Diabetes (DM), Retinopathy, Diabetic, Pupil Dilation","enrollment":84},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":"Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma","enrollment":600},{"nctId":"NCT07498257","phase":"NA","title":"Adaptation and RCT of Written Exposure Therapy for Adolescents","status":"NOT_YET_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-03-05","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":48},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT04840602","phase":"PHASE2","title":"Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-01-05","conditions":"Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia","enrollment":92},{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Advanced Solid Malignancies","enrollment":41},{"nctId":"NCT03809377","phase":"","title":"Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects (RTGene 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-05-09","conditions":"Cancer","enrollment":25},{"nctId":"NCT07497763","phase":"NA","title":"A Brief Case Management Intervention to Promote Personal Recovery and Prevent Psychiatric Involuntary Readmissions: a Randomised Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Stéphane Morandi","startDate":"2026-04","conditions":"Psychiatric Disorder, Involuntary Psychiatric Hospitalization","enrollment":252},{"nctId":"NCT05327127","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kowa Research Institute, Inc.","startDate":"2022-11-14","conditions":"NASH","enrollment":228},{"nctId":"NCT07498179","phase":"NA","title":"Intervention Programme for Seniors","status":"ENROLLING_BY_INVITATION","sponsor":"Diana Ďuricová","startDate":"2026-04-20","conditions":"Healthy","enrollment":200},{"nctId":"NCT05131022","phase":"PHASE1","title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2022-04-13","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":572},{"nctId":"NCT07496099","phase":"NA","title":"Effects of Post-Isometric Relaxation and Myofascial Release on Low Back Pain With Lower Cross Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of Karachi","startDate":"2026-03-25","conditions":"Low Back Pain, Mechanical, Lower Cross Syndrome, Hamstring Muscle Tightness","enrollment":60},{"nctId":"NCT07413458","phase":"NA","title":"Virtual Reality (VR) NATURE - Alcohol Use Disorder (AUD)","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2026-02-16","conditions":"Alcohol Use Disorder","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ERYTHEMA"},{"count":1,"reaction":"APPLICATION SITE ERYTHEMA"},{"count":1,"reaction":"APPLICATION SITE IRRITATION"},{"count":1,"reaction":"APPLICATION SITE PRURITUS"},{"count":1,"reaction":"APPLICATION SITE SWELLING"},{"count":1,"reaction":"BURNING SENSATION"},{"count":1,"reaction":"BURNS FIRST DEGREE"},{"count":1,"reaction":"CHEMICAL INJURY"},{"count":1,"reaction":"CONTUSION"},{"count":1,"reaction":"HYPERSENSITIVITY"}],"_approvalHistory":[{"date":"20160721","type":"SUPPL","sponsor":"PURE SOURCE","applicationNumber":"ANDA076239"},{"date":"20040824","type":"ORIG","sponsor":"PURE SOURCE","applicationNumber":"ANDA076239"},{"date":"20160721","type":"SUPPL","sponsor":"PURE SOURCE","applicationNumber":"ANDA076239"}],"publicationCount":3216,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Comparator"],"phase":"marketed","status":"active","brandName":"Treatment 5","genericName":"Treatment 5","companyName":"EyeGene Inc.","companyId":"eyegene-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ETC-1002 is a small molecule intervention being studied in clinical trials for various conditions, including hypercholesterolemia. It is being tested in combination with atorvastatin, a commonly used cholesterol-lowering medication, in a placebo-controlled study.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"supplemented","approval_date":"2004-08-24T00:00:00.000Z","mah":"PURE SOURCE","brand_name_local":null,"application_number":"ANDA076239"}],"trialStats":{"total":4,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}